+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Postoperative Pain- Market Insight, Epidemiology and Market Forecast - 2030

  • ID: 5357290
  • Report
  • July 2021
  • Region: Global
  • 336 pages
  • DelveInsight

FEATURED COMPANIES

  • AcelRx Pharmaceuticals
  • Bausch & Lomb
  • Esteve Pharmaceuticals
  • Hyloris Pharmaceuticals
  • Menarini Group
  • Ocular Therapeutix

This "Postoperative Pain - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Postoperative Pain, historical and forecasted epidemiology as well as the Postoperative Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Postoperative Pain market report provides current treatment practices, emerging drugs, Postoperative Pain market share of the individual therapies, current and forecasted Postoperative Pain market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Postoperative Pain treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Postoperative Pain Disease Understanding and Treatment Algorithm

The Postoperative Pain market report gives a thorough understanding of the Postoperative Pain by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Postoperative Pain.

Treatment

It covers the details of conventional and current medical therapies available in the Postoperative Pain market for the treatment of the condition. It also provides Postoperative Pain treatment algorithms and guidelines in the United States, Europe, and Japan.

Postoperative Pain Epidemiology

The Postoperative Pain epidemiology division provide insights about historical and current Postoperative Pain patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Postoperative Pain epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Postoperative Pain Epidemiology

The epidemiology segment also provides the Postoperative Pain epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Postoperative Pain Drug Chapters

Drug chapter segment of the Postoperative Pain report encloses the detailed analysis of Postoperative Pain marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Postoperative Pain clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Postoperative Pain treatment.

Postoperative Pain Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Postoperative Pain treatment.

Postoperative Pain Market Outlook

The Postoperative Pain market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Postoperative Pain market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Postoperative Pain market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Postoperative Pain market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Postoperative Pain market in 7MM.

The United States Market Outlook

This section provides the total Postoperative Pain market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Postoperative Pain market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Postoperative Pain market size and market size by therapies in Japan is also mentioned.

Postoperative Pain Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Postoperative Pain market or expected to get launched in the market during the study period 2017-2030. The analysis covers Postoperative Pain market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Postoperative Pain Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Postoperative Pain key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Postoperative Pain emerging therapies.

Reimbursement Scenario in Postoperative Pain

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, the publisher takes reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL-Views

To keep up with current market trends, the publisher takes KOLs and SME's opinion working in Postoperative Pain domain through primary research to fill the data gaps and validate the secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Postoperative Pain market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the Postoperative Pain Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Postoperative Pain, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Postoperative Pain epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Postoperative Pain are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Postoperative Pain market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Postoperative Pain market

Report Highlights

  • In the coming years, Postoperative Pain market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Postoperative Pain R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Postoperative Pain. Launch of emerging therapies will significantly impact the Postoperative Pain market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Postoperative Pain
  • The in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Postoperative Pain Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Postoperative Pain Pipeline Analysis
  • Postoperative Pain Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Postoperative Pain Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Postoperative Pain Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Postoperative Pain Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions Answered

Market Insights:

  • What was the Postoperative Pain market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Postoperative Pain total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Postoperative Pain market size during the forecast period (2017-2030)?
  • At what CAGR, the Postoperative Pain market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Postoperative Pain market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Postoperative Pain market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Postoperative Pain?
  • What is the historical Postoperative Pain patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Postoperative Pain in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Postoperative Pain?
  • Out of all 7MM countries, which country would have the highest prevalent population of Postoperative Pain during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

- Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Postoperative Pain treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Postoperative Pain in the USA, Europe, and Japan?
  • What are the Postoperative Pain marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Postoperative Pain?
  • How many therapies are developed by each company for Postoperative Pain treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Postoperative Pain treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Postoperative Pain therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Postoperative Pain and their status?
  • What are the key designations that have been granted for the emerging therapies for Postoperative Pain?
  • What are the global historical and forecasted market of Postoperative Pain?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Postoperative Pain market
  • To understand the future market competition in the Postoperative Pain market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Postoperative Pain in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Postoperative Pain market
  • To understand the future market competition in the Postoperative Pain market
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AcelRx Pharmaceuticals
  • Bausch & Lomb
  • Esteve Pharmaceuticals
  • Hyloris Pharmaceuticals
  • Menarini Group
  • Ocular Therapeutix

1 Report Introduction

2 Postoperative Pain Market Overview at a Glance
2.1 Market Share (%) Distribution of Postoperative Pain in 2018
2.2 Market Share (%) Distribution of Postoperative Pain in 2030

3 Postoperative Pain Market: Future Perspective

4 Executive Summary of Postoperative Pain

5 Disease Background and Overview
5.1 Introduction
5.2 Transition from Acute to Chronic Pain
5.2.1 Elective or Planned Procedures
5.2.2 Common Types of Acute Postoperative Pains
5.3 Pathophysiology of Acute Pain
5.3.1 Formation of reflexes in postoperative pain
5.3.1.1 Segmental reflexes
5.3.1.2 Suprasegmental reflexes
5.3.1.3 Cortical responses
5.3.2 Negative effects of postoperative pain on various organ systems
5.3.2.1 Changes in respiratory functions
5.3.2.2 Cardiovascular changes
5.3.2.3 Gastrointestinal and urinary changes
5.3.2.4 Neuroendocrine and metabolic changes
5.3.3 Psychological effects of postoperative pain
5.3.4 Late effects of insufficient postoperative analgesia
5.3.5 Chronic postoperative pain
5.4 Factors affecting postoperative pain
5.5 Diagnosis of Postoperative Pain
5.5.1 Medical history, physical examination, and specific evaluation of pain
5.5.2 Measuring pain
5.5.3 Various Grading Scales used for Diagnosis of Acute Pain
5.5.3.1 Visual Analogue Scale
5.5.3.2 Verbal Rating Scale
5.5.3.3 Graded Chronic Pain Scale (GCPS)
5.5.3.4 Numeric Rating Scale (NRS)
5.5.4 Verbal methods of pain assessment
5.5.5 Multidimensional methods of pain assessment
5.5.6 Nonverbal methods of pain assessment
5.5.7 Diagnostic Algorithm
5.5.8 Guidelines
5.5.8.1 Guidelines on the Management of Postoperative Pain
5.5.8.2 Goals and Elements of the Initial Assessment
5.6 Treatment
5.6.1 Pharmacological Therapies
5.6.2 Multimodal analgesia
5.6.3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.6.3.1 Nonselective COX inhibitors
5.6.3.2 Preferential COX-2 inhibitors
5.6.3.3 Selective COX-2 inhibitors - coxibs
5.6.4 Opioids
5.6.4.1 Weak opioid analgesics
5.6.4.2 Strong opioid analgesics
5.6.5 Non-opioid analgesics
5.6.5.1 Paracetamol (acetaminophen)
5.6.5.2 Metamizole
5.6.6 Procedure-specific analgesia
5.6.6.1 Discharge planning
5.6.7 Regional anesthesia
5.6.8 Non-Pharmacological Methods to Treat Acute Pain
5.6.8.1 Cognitive dysfunction
5.6.8.2 Herbal medicine
5.6.8.3 Homeopathy
5.6.8.4 Meditation
5.6.9 Physical methods
5.6.9.1 Cold
5.6.9.2 Heat
5.6.9.3 Transcutaneous electrical nerve stimulation (TENS) in Acute Post-Operative Pain
5.6.9.4 Acupuncture
5.6.9.5 Hypnosis
5.6.9.6 Immobilization
5.6.9.7 Massage
5.6.10 Intravenous Patient-Controlled Analgesia (PCA)
5.6.10.1 Patient-Controlled Epidural Analgesia
5.6.11 Nerve Blocks
5.6.12 Pediatric Pain Management
5.6.13 Treatment Algorithm for Acute Postoperative Pain
5.6.14 Guidelines for Acute Pain
5.6.14.1 Recent advances in acute pain management: understanding the mechanisms of acute pain, the prescription of opioids, and the role of multimodal pain therapy (2017)
5.6.14.2 Management of Postoperative Pain: A Clinical Practice Guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council (2017)
5.6.15 Recommendations for Pre- and Intra-operative Pain Management by The European Society of Regional Anaesthesia and Pain Therapy

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Methodology of Epidemiology
6.3 Total number of Incident cases of Postoperative Pain in the 7MM
6.4 Epidemiology of Postoperative Pain in the 7MM
6.5 United States
6.5.1 Total number of surgical procedures in the US
6.5.2 Total number of Incident cases of Postoperative Pain in the US
6.5.3 Severity-specific incident cases of Postoperative Pain in the US
6.6 EU5
6.6.1 Germany
6.6.1.1 Total number of surgical procedures in Germany
6.6.1.2 Total number of Incident cases of Postoperative Pain in Germany
6.6.1.3 Severity-specific incident cases of Postoperative Pain in Germany
6.6.2 France
6.6.2.1 Total number of surgical procedures in France
6.6.2.2 Total number of Incident cases of Postoperative Pain in France
6.6.2.3 Severity-specific incident cases of Postoperative Pain in France
6.6.3 Italy
6.6.3.1 Total number of surgical procedures in Italy
6.6.3.2 Total number of Incident cases of Postoperative Pain in Italy
6.6.3.3 Severity-specific incident cases of Postoperative Pain in Italy
6.6.4 Spain
6.6.4.1 Total number of surgical procedures in Spain
6.6.4.2 Total number of Incident cases of Postoperative Pain in Spain
6.6.4.3 Severity-specific incident cases of Postoperative Pain in Spain
6.6.5 United Kingdom
6.6.5.1 Total number of surgical procedures in the UK
6.6.5.2 Total number of Incident cases of Postoperative Pain in the UK
6.6.5.3 Severity-specific incident cases of Postoperative Pain in the UK
6.7 Japan
6.7.1 Total number of surgical procedures in Japan
6.7.2 Total number of Incident cases of Postoperative Pain in Japan
6.7.3 Severity-specific incident cases of Postoperative Pain in Japan

7 Patient Journey

8 Marketed Drugs
8.1 Marketed Drugs Key-cross Competition
8.2 Enanplus/Takudex (Dexketoprofen/Tramadol): Menarini Group/Guidotti Farma
8.2.1 Product Description
8.2.2 Regulatory Milestones
8.2.3 Other Developmental activities
8.2.4 Clinical Development
8.2.5 Clinical Trials Information
8.2.6 Safety and Efficacy
8.2.7 Product Profile
8.3 Dsuvia/Dzuveo (Sufentanil): AcelRx Pharmaceuticals
8.3.1 Product Description
8.3.2 Regulatory Milestones
8.3.3 Other Developmental activities
8.3.4 Clinical Development
8.3.5 Clinical Trials Information
8.3.6 Safety and Efficacy
8.3.7 Product Profile
8.4 Zalviso: AcelRx Pharmaceuticals
8.4.1 Product Description
8.4.2 Regulatory Milestones
8.4.3 Other Developmental activities
8.4.4 Clinical Development
8.4.5 Clinical Trials Information
8.4.6 Safety and Efficacy
8.4.7 Product Profile
8.5 Olinvyk (Olinvo) (oliceridine): Trevena, Inc.
8.5.1 Product Description
8.5.2 Regulatory Milestones
8.5.3 Other Development Activities
8.5.4 Clinical Development
8.5.5 Clinical Trials Information
8.5.6 Safety and Efficacy
8.5.7 Product Profile
8.6 Zynrelef (HTX-011): Heron Therapeutics
8.6.1 Product Description
8.6.2 Regulatory Milestones
8.6.3 Other Developmental Activities
8.6.4 Clinical Development
8.6.5 Clinical Trials Information
8.6.6 Safety and Efficacy
8.6.7 Product Profile
8.7 Xaracoll: Innocoll Pharmaceuticals
8.7.1 Product Description
8.7.2 Regulatory Milestones
8.7.3 Other Developmental activities
8.7.4 Clinical Development
8.7.5 Clinical Trials Information
8.7.6 Safety and Efficacy
8.7.7 Product Profile
8.8 Posimir (bupivacaine solution): DURECT Corporation
8.8.1 Product Description
8.8.2 Regulatory Milestones
8.8.3 Other Developmental activities
8.8.4 Clinical Development
8.8.5 Clinical Trials Information
8.8.6 Safety and Efficacy
8.8.7 Product Profile
8.9 Exparel: Pacira Pharmaceuticals
8.9.1 Product Description
8.9.2 Regulatory Milestones
8.9.3 Other Developmental activities
8.9.4 Clinical Development
8.9.5 Clinical Trials Information
8.9.6 Safety and Efficacy
8.9.7 Product Profile
8.10 Anjeso: Baudax Bio
8.10.1 Product Description
8.10.2 Regulatory Milestones
8.10.3 Other Development Activities
8.10.4 Clinical Development
8.10.5 Clinical Trials Information
8.10.6 Safety and Efficacy
8.10.7 Product Profile
8.11 Prolensa (bromfenac ophthalmic solution) 0.07%: Bausch & Lomb
8.11.1 Product Description
8.11.2 Regulatory Milestones
8.11.3 Clinical Development
8.11.4 Clinical Trials Information
8.11.5 Safety and Efficacy
8.11.6 Product Profile
8.12 Dextenza: Ocular Therapeutix
8.12.1 Product Description
8.12.2 Regulatory Milestones
8.12.3 Other Developmental activities
8.12.4 Clinical Development
8.12.5 Clinical Trials Information
8.12.6 Safety and Efficacy
8.12.7 Product Profile
8.13 Inveltys: Kala Pharmaceuticals, Inc.
8.13.1 Product Description
8.13.2 Regulatory Milestones
8.13.3 Other Developmental activities
8.13.4 Clinical Development
8.13.5 Clinical Trials Information
8.13.6 Safety and Efficacy
8.13.7 Product Profile
8.14 Penthrox: Medical Developments International Ltd (MVP)
8.14.1 Product Description
8.14.2 Regulatory Milestones
8.14.3 Other Developmental activities
8.14.4 Clinical Development
8.14.5 Clinical Trials Information
8.14.6 Safety and Efficacy
8.14.7 Product Profile
8.15 Lotemax SM (loteprednol etabonate ophthalmic gel): Bausch & Lomb
8.15.1 Product Description
8.15.2 Regulatory Milestones
8.15.3 Safety and Efficacy
8.15.4 Product Profile
8.16 Maxigesic: Hyloris Pharmaceuticals/AFT Pharmaceuticals
8.16.1 Product Description
8.16.2 Regulatory Milestone
8.16.3 Other Developmental Activities
8.16.4 Clinical Development
8.16.5 Clinical Trials Information
8.16.6 Safety and Efficacy
8.16.7 Product Profile

9 Emerging Drugs
9.1 Key Cross Competition
9.2 CR845/Difelikefalin: Cara Therapeutics
9.2.1 Product Description
9.2.2 Other Developmental Activities
9.2.3 Clinical Development
9.2.4 Clinical Trials Information
9.2.5 Safety and Efficacy
9.2.6 Product Profile
9.3 VVZ-149 Injections: Vivozon, Inc.
9.3.1 Product Description
9.3.2 Other Developmental Activities
9.3.3 Clinical Development
9.3.4 Clinical Trials Information
9.3.5 Safety and Efficacy
9.3.6 Product Profile
9.4 Tramadol IV: Avenue Therapeutics, Inc.
9.4.1 Product Description
9.4.2 Other Developmental Activities
9.4.3 Clinical Development
9.4.4 Clinical Trials Information
9.4.5 Safety and Efficacy
9.4.6 Product Profile
9.5 F14 (sustained-release celecoxib)/mdc-CWM (Celecoxib): Arthritis Innovation Corporation/MedinCell
9.5.1 Product Description
9.5.2 Other Developmental Activities
9.5.3 Clinical Development
9.5.4 Clinical Trials Information
9.5.5 Safety and Efficacy
9.5.6 Product Profile
9.6 Nefopam hydrochloride and paracetamol: Unither Pharmaceuticals
9.6.1 Product Description
9.6.2 Clinical Development
9.6.3 Clinical Trials Information
9.6.4 Product Profile
9.7 Co-crystal E-58425 (Tramadol/Celecoxib): Esteve Pharmaceuticals
9.7.1 Product Description
9.7.2 Other Developmental Activities
9.7.3 Clinical Development
9.7.4 Clinical Trials Information
9.7.5 Safety and Efficacy
9.7.6 Product Profile
9.8 APP13007: Formosa Pharmaceuticals
9.8.1 Drug Description
9.8.2 Regulatory Milestones
9.8.3 Clinical Development
9.8.4 Clinical Trials Information
9.8.5 Safety and Efficacy
9.8.6 Product Profile
9.9 NTM-001 (Ketorolac Pre-Mixed Bag): Neumentum Pharmaceuticals
9.9.1 Product Description
9.9.2 Other Developmental Activities
9.9.3 Clinical Developmental Activities
9.9.4 Safety and Efficacy
9.9.5 Product Profile
9.10 ACP-044: Acadia Pharmaceuticals Inc.
9.10.1 Product Description
9.10.2 Other Developmental Activities
9.10.3 Clinical Development
9.10.4 Clinical Trials Information
9.10.5 Product Profile
9.11 NVK-009 (Pregabalin and Acetaminophen): Nevakar, Inc.
9.11.1 Product Description
9.11.2 Clinical Development
9.11.3 Clinical Trials Information
9.11.4 Product Profile
9.12 TLC590: Taiwan Liposome Company (TLC)
9.12.1 Product Description
9.12.2 Other Developmental Activities
9.12.3 Clinical Development
9.12.4 Clinical Trials Information
9.12.5 Safety and Efficacy
9.12.6 Product Profile
9.13 MR-107A-01: Viatris Inc. (formerly known as Mylan Inc.)
9.13.1 Product Description
9.13.2 Other Developmental Activities
9.13.3 Clinical Development
9.13.4 Clinical Trials Information
9.13.5 Product Profile
9.14 TPU-006 (Dexmedetomidine Transdermal System (DMTS)): Teikoku Pharma USA, Inc.
9.14.1 Product Description
9.14.2 Other Developmental Activities
9.14.3 Clinical Development
9.14.4 Clinical Trials Information
9.14.5 Safety and Efficacy
9.14.6 Product Profile
9.15 SAF312: Novartis Pharmaceuticals
9.15.1 Product Description
9.15.2 Clinical Development
9.15.3 Clinical Trials Information
9.15.4 Safety and Efficacy
9.15.5 Product Profile
9.16 OCS-01: Oculis
9.16.1 Product Description
9.16.2 Other Developmental Activities
9.16.3 Clinical Development
9.16.4 Clinical Trials Information
9.16.5 Safety and Efficacy
9.16.6 Product Profile
9.17 PRF110: PainReform LTD
9.17.1 Product Description
9.17.2 Other Developmental Activities
9.17.3 Clinical Development
9.17.4 Clinical Trials Information
9.17.5 Safety and Efficacy
9.17.6 Product Profile
9.18 Vocacapsaicin (CA-008): Concentric Analgesics
9.18.1 Product Description
9.18.2 Other Developmental Activities
9.18.3 Clinical Development
9.18.4 Clinical Trials Information
9.18.5 Safety and Efficacy
9.18.6 Product Profile
9.19 Nepafenac PPDS/Nepafenac Evolute: Mati Therapeutics Inc.
9.19.1 Product Description
9.19.2 Other Developmental Activities
9.19.3 Clinical Development
9.19.4 Clinical Trials Information
9.19.5 Safety and Efficacy
9.19.6 Product Profile

10 Postoperative Pain: Seven Major Market Analysis
10.1 Key Findings
10.2 Methodology of Postoperative Pain Market
10.3 Market Size of Postoperative Pain in the 7MM Countries
10.4 Market Size of Postoperative Pain by Therapies in the 7MM Countries
10.5 Comparison of 7MM Postoperative Pain Market
10.6 Discharge Prescription Pattern of Various Analgesic in Postoperative Pain among the United States and EU
10.7 Emerging Drug Analysis
10.8 7MM Market Outlook
10.9 United States Market Size
10.9.1 Total Market Size of Postoperative Pain in the United States
10.9.2 Market Size by Therapies of Postoperative Pain in the United States
10.10 EU-5 Market Size
10.10.1 Germany
10.10.1.1 Total Market size of Postoperative Pain in Germany
10.10.1.2 Market Size by Therapies of Postoperative Pain in Germany
10.10.2 France
10.10.2.1 Total Market size of Postoperative Pain in France
10.10.2.2 Market Size of Postoperative Pain by Therapies in France
10.10.3 Italy
10.10.3.1 Total Market Size of Postoperative Pain in Italy
10.10.3.2 Market Size of Postoperative Pain by Therapies in Italy
10.10.4 Spain
10.10.4.1 Total Market Size of Postoperative Pain in Spain
10.10.4.2 Market Size of Postoperative Pain by Therapies in Spain
10.10.5 United Kingdom
10.10.5.1 Total Market Size of postoperative pain in the United Kingdom
10.10.5.2 Market Size of Postoperative Pain by Therapies in the United Kingdom
10.11 Japan
10.11.1 Total Market Size of Postoperative Pain in Japan
10.11.2 Market Size of Postoperative Pain by Therapies in Japan

11 KOL Views
11.1 US KOL Views
11.2 EU5 and Japan KOL Views

12 Market Drivers

13 Market Barriers

14 SWOT Analysis

15 Unmet Needs

16 Reimbursement and Market Access

17 Appendix
17.1 Bibliography
17.2 Report Methodology

18 Publisher Capabilities

19 Disclaimer

20 About the Publisher

List of Tables
Table 1 Summary of Postoperative Pain, Market, Epidemiology, and Key Events (2018-2030)
Table 2 Common Types of Pain (related to acute postoperative pain)
Table 3 Graded Chronic Pain Scale (GCPS)
Table 4 Unidimensional Pain Assessment Tools
Table 5 Multidimensional Pain Assessment Tools
Table 6 Preoperative Assessment and Patient Education Recommendations
Table 7 Postoperative Assessment and Patient Education Recommendations
Table 8 Perioperative Pain Management Considerations and Recommendations
Table 9 Recommended: Pre- and intra-operative interventions for Inguinal Hernia Repair
Table 10 Recommended: Pre- and intra-operative interventions for Hallux Valgus Repair Surgery
Table 11 Recommendations: Pain management after complex spine surgery
Table 12 Overall recommendations for pain management in patients undergoing elective caesarean section
Table 13 Total number of Incident cases of Postoperative Pain in the 7MM (2018-2030) (in ‘000’)
Table 14 Total number of surgical procedures in the US (2018-2030) (in ‘000’)
Table 15 Total number of Incident cases of Postoperative Pain in the US (2018-2030) (in ‘000’)
Table 16 Severity-specific incident cases of Postoperative Pain in the US (2018-2030) (in ‘000’)
Table 17 Total number of surgical procedures in Germany (2018-2030) (in ‘000’)
Table 18 Total number of Incident cases of Postoperative Pain in Germany (2018-2030) (in ‘000’)
Table 19 Severity-specific incident cases of Postoperative Pain in Germany (2018-2030) (in ‘000’)
Table 20 Total number of surgical procedures in France (2018-2030) (in ‘000’)
Table 21 Total number of Incident cases of Postoperative Pain in France (2018-2030) (in ‘000’)
Table 22 Severity-specific incident cases of Postoperative Pain in France (2018-2030) (in ‘000’)
Table 23 Total number of surgical procedures in Italy (2018-2030) (in ‘000’)
Table 24 Total number of Incident cases of Postoperative Pain in Italy (2018-2030) (in ‘000’)
Table 25 Severity-specific incident cases of Postoperative Pain in Italy (2018-2030) (in ‘000’)
Table 26 Total number of surgical procedures in Spain (2018-2030) (in ‘000’)
Table 27 Total number of Incident cases of Postoperative Pain in Spain (2018-2030) (in ‘000’)
Table 28 Severity-specific incident cases of Postoperative Pain in Spain (2018-2030) (in ‘000’)
Table 29 Total number of surgical procedures in the UK (2018-2030) (in ‘000’)
Table 30 Total number of Incident cases of Postoperative Pain in the UK (2018-2030) (in ‘000’)
Table 31 Severity-specific incident cases of Postoperative Pain in the UK (2018-2030) (in ‘000’)
Table 32 Total number of surgical procedures in Japan (2018-2030) (in ‘000’)
Table 33 Total number of Incident cases of Postoperative Pain in Japan (2018-2030) (in ‘000’)
Table 34 Severity-specific incident cases of Postoperative Pain in Japan (2018-2030) (in ‘000’)
Table 35 Comparison of Marketed Drugs
Table 36 Dexketoprofen/Tramadol, Clinical Trial Description, 2021
Table 37 Dsuvia, Clinical Trial Description, 2021
Table 38 Zalviso, Clinical Trial Description, 2021
Table 39 Olinvyk, Clinical Trial Description, 2021
Table 40 Zynrelef (HTX-011), Clinical Trial Description, 2021
Table 41 XaraColl, Clinical Trial Description, 2021
Table 42 Posimir (bupivacaine solution), Clinical Trial Description, 2021
Table 43 Exparel, Clinical Trial Description, 2021
Table 44 ANJESO (N1539), Clinical Trial Description, 2021
Table 45 Prolensa (bromfenac ophthalmic solution) 0.07%, Clinical Trial Description, 2021
Table 46 Dextenza, Clinical Trial Description, 2021
Table 47 Inveltys, Clinical Trial Description, 2021
Table 48 Penthrox, Clinical Trial Description, 2021
Table 49 Maxigesic, Clinical Trial Description, 2021
Table 50 Comparison of emerging drugs under development (1)
Table 51 Comparison of emerging drugs under development (2)
Table 52 Comparison of emerging drugs under development (3)
Table 53 Comparison of emerging drugs under development (4)
Table 54 CR845, Clinical Trial Description, 2021
Table 55 VVZ-149, Clinical Trial Description, 2021
Table 56 Tramadol, Clinical Trial Description, 2021
Table 57 F14 (sustained release celecoxib), Clinical Trial Description, 2021
Table 58 Nefopam hydrochloride 30 mg /Paracetamol 500 mg X2 , Clinical Trial Description, 2021
Table 59 Co-crystal E-58425 (Tramadol/Celecoxib), Clinical Trial Description, 2021
Table 60 APP13007, Clinical Trial Description, 2021
Table 61 ACP-044, Clinical Trial Description, 2021
Table 62 NVK-009, Clinical Trial Description, 2021
Table 63 TLC590, Clinical Trial Description, 2021
Table 64 MR-107A-01, Clinical Trial Description, 2021
Table 65 TPU-006, Clinical Trial Description, 2021
Table 66 SAF312, Clinical Trial Description, 2021
Table 67 OCS-01, Clinical Trial Description, 2021
Table 68 PRF 110, Clinical Trial Description, 2021
Table 69 Vocacapsaicin (CA-008), Clinical Trial Description, 2021
Table 70 Nepafenac PPDS, Clinical Trial Description, 2021
Table 71 Market size of postoperative pain in the 7MM, in USD million (2018-2030)
Table 72 Market size of postoperative pain by therapies in the 7MM, in USD million (2018-2030)
Table 73 Market size of postoperative pain in the United States, USD million (2018-2030)
Table 74 Market size of postoperative pain by therapies in the US, in USD million (2018-2030)
Table 75 Market size of postoperative pain in Germany, in USD million (2018-2030)
Table 76 Market size of postoperative pain by therapies in Germany, in USD million (2018-2030)
Table 77 Market size of postoperative pain in France, in USD million (2018-2030)
Table 78 Market size of postoperative pain by therapies in France, in USD million (2018-2030)
Table 79 Market size of postoperative pain in Italy, in USD million (2018-2030)
Table 80 Market size of postoperative pain by therapies in Italy, in USD million (2018-2030)
Table 81 Market size of postoperative pain in Spain, in USD million (2018-2030)
Table 82 Market size of postoperative pain by therapies in Spain, in USD million (2018-2030)
Table 83 Market Size of postoperative pain in the UK, in USD million (2018-2030)
Table 84 Market size of postoperative pain by therapies in the UK, in USD million (2018-2030)
Table 85 Market Size of postoperative pain in Japan, in USD million (2018-2030)
Table 86 Market size of postoperative pain by therapies in Japan, in USD million (2018-2030)

Note: Product cover images may vary from those shown
  • Acadia Pharmaceuticals Inc.
  • AcelRx Pharmaceuticals
  • AFT Pharmaceuticals
  • Arthritis Innovation Corporation
  • Avenue Therapeutics, Inc.
  • Baudax Bio
  • Bausch & Lomb
  • Cara Therapeutics
  • Concentric Analgesics
  • DURECT Corporation
  • Esteve Pharmaceuticals
  • Formosa Pharmaceuticals
  • Guidotti Farma
  • Heron Therapeutics
  • Hyloris Pharmaceuticals
  • Innocoll Pharmaceuticals
  • Kala Pharmaceuticals, Inc.
  • Mati Therapeutics Inc.
  • Medical Developments International Ltd (MVP)
  • MedinCell
  • Menarini Group
  • Neumentum Pharmaceuticals
  • Nevakar, Inc.
  • Novartis Pharmaceuticals
  • Ocular Therapeutix
  • Oculis
  • Pacira Pharmaceuticals
  • PainReform LTD
  • Taiwan Liposome Company (TLC)
  • Teikoku Pharma USA, Inc.
  • Trevena, Inc.
  • Unither Pharmaceuticals
  • Viatris Inc. (formerly known as Mylan Inc.)
  • Vivozon, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll